Introduction/Background About 80 percent of patients of ovarian cancer relapse following optimal cytoreduction and chemotherapy. A majority of these patients are in poor general condition due to conglomeration of factors leading to malnutrition and poor immunity. The 10 year survival of these patients is less than 15%. A historical debate continues to exist regarding treatment following relapse in platinum sensitive disease. The objective of this prospective study was to evaluate the short term outcomes of patients undergoing secondary cytoreductive surgery at our institute.

Methodology Twenty-eight patients of histological and biochemical relapsed ovarian cancers were operated between April 2017 and December 2021. The selection criterion of platinum sensitivity and AGO DESKTOP III with a good performance score (ECOG 0–2), no ascites and a previous complete cytoreduction. Disease free survival was calculated from the date of last treatment (chemotherapy or surgery) to the date of recurrence/death, whichever is the earliest, or upto 31–01-2022 in patients without evidence of recurrent disease

• Download figure
• Open in new tab
• Download powerpoint

Abstract #134 Figure 1

Kaplan Meir curve showing survival

Results A total of 28 women underwent surgery, of which 17 underwent primary surgery and 11 underwent interval cytoreduction. A total of 13 patients (46.4%) had experienced recurrence, 13 (46.4%) had no recurrence and 2 (7.17%) are still undergoing therapy as of 31–01-2022. The mean disease free survival (DFS) in the recurred group was 14.29 months (range 1–34 months, median- 19.5months) and in the non recurred group was 20.515months (range 7–51 months, median -17.75 months).Morbidity was evaluated using Clavien Dindo Morbidity Index

Conclusion The mean DFS following secondary CRS is 20.51months including relapse following the secondary CRS which is significant enough to provide the benefit of surgery in a select population of patients

Disclosures Nil